According to @ReutersBiz, European pharmaceutical shares were mostly firm even after U.S. President Donald Trump announced new tariffs on branded pharmaceutical imports effective October 1. According to @ReutersBiz, the report highlights the tariff start date but does not provide company-level details or specific tariff rates, with the immediate market response in European pharma described as largely resilient. According to @ReutersBiz, the update does not reference broader cross-asset moves or crypto market reactions, indicating no reported immediate spillover into digital assets in this dispatch. According to @ReutersBiz, the next concrete catalyst for traders is the October 1 implementation timing, which sets a clear headline-risk checkpoint for positioning and risk management.